Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LXRX Stock Forecast 2025-2026
$0.67
Current Price
$243.87M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LXRX Price Targets
+795.5%
To High Target of $6.00
+79.1%
To Median Target of $1.20
+4.5%
To Low Target of $0.70
LXRX Price Momentum
-10.7%
1 Week Change
+24.1%
1 Month Change
-63.2%
1 Year Change
-9.5%
Year-to-Date Change
-72.7%
From 52W High of $2.45
+139.3%
From 52W Low of $0.28
📊 TOP ANALYST CALLS
Did LXRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lexicon is one of their latest high-conviction picks.
Latest LXRX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, LXRX has a bullish consensus with a median price target of $1.20 (ranging from $0.70 to $6.00). The overall analyst rating is Buy (7.6/10). Currently trading at $0.67, the median forecast implies a 79.1% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 795.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXRX Analyst Ratings
3
Buy
2
Hold
0
Sell
LXRX Price Target Range
Low
$0.70
Average
$1.20
High
$6.00
Current: $0.67
Latest LXRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 7, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Mar 7, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $6.00 |
| Mar 4, 2025 | Leerink Partners | Roanna Ruiz | Market Perform | Downgrade | $1.00 |
| Mar 3, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Jan 29, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Jan 29, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Dec 23, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 25, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 22, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 13, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $6.00 |
| Nov 1, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Oct 30, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
Lexicon Pharmaceuticals, Inc. (LXRX) Competitors
The following stocks are similar to Lexicon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexicon Pharmaceuticals, Inc. (LXRX) Financial Data
Lexicon Pharmaceuticals, Inc. has a market capitalization of $243.87M with a P/E ratio of 0.0x. The company generates $31.21M in trailing twelve-month revenue with a 98.0% profit margin.
Revenue growth is +11.7% quarter-over-quarter, while maintaining an operating margin of -2,034.8% and return on equity of -86.1%.
Valuation Metrics
Market Cap
$243.87M
Enterprise Value
$155.30M
P/E Ratio
0.0x
PEG Ratio
-1.1x
Price/Sales
7.8x
Growth & Margins
Revenue Growth (YoY)
+11.7%
Gross Margin
+97.6%
Operating Margin
-2,034.8%
Net Margin
+98.0%
EPS Growth
+11.7%
Financial Health
Cash/Price Ratio
+80.0%
Current Ratio
2.2x
Debt/Equity
86.4x
ROE
-86.1%
ROA
-28.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lexicon Pharmaceuticals, Inc. (LXRX) Business Model
About Lexicon Pharmaceuticals, Inc.
What They Do
Develops breakthrough treatments for human diseases.
Business Model
The company utilizes advanced gene knockout technology to discover and develop therapies for various medical conditions, focusing on areas with unmet medical needs. Lexicon Pharmaceuticals generates revenue through the successful development and commercialization of its innovative pharmaceutical products, often collaborating with other organizations to advance its clinical programs.
Additional Information
Lexicon is actively engaged in research for conditions such as diabetes, carcinoid syndrome, and heart diseases. The company collaborates with the scientific community and regulatory bodies to enhance its chances of regulatory approval, positioning itself as a significant player in the biomedical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
285
CEO
Mr. Lonnel Coats
Country
United States
IPO Year
2000
Website
www.lexpharma.comLexicon Pharmaceuticals, Inc. (LXRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
Jun 10, 2025
By Zacks Equity Research
Analyst Blog
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Jun 06, 2025
By Zacks Equity Research
Analyst Blog
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
Jun 06, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 12:50 p.m. ET. Access details are on their website.
Why It Matters
Lexicon Pharmaceuticals' participation in a major healthcare conference may provide insights into its strategies and future prospects, potentially affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals is conducting a Phase 3 trial for sotagliflozin in hypertrophic cardiomyopathy, enrolling patients across 20 countries, with full site operations expected by Q3 2025.
Why It Matters
Lexicon's trial for sotagliflozin in hypertrophic cardiomyopathy could lead to significant market opportunities and revenue potential, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals will hold its Q1 2025 earnings conference call on May 13, 2025, at 5:00 PM ET, featuring key executives and analysts from major firms.
Why It Matters
The earnings call provides insights into Lexicon Pharmaceuticals' financial health and strategic direction, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
1 month ago
Quick Summary
Lexicon Pharmaceuticals reported a strong start to 2025, securing an exclusive license with Novo Nordisk for LX9851 and advancing pilavapadin to Phase 3 for diabetic pain.
Why It Matters
Lexicon Pharmaceuticals' strong start in 2025, strategic partnership with Novo Nordisk, and progress in clinical trials signal growth potential, enhancing investor confidence in future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals (LXRX) reported a quarterly loss of $0.07 per share, better than the expected loss of $0.10, and improved from a loss of $0.20 per share a year prior.
Why It Matters
Lexicon Pharmaceuticals' smaller-than-expected quarterly loss indicates improving financial performance, potentially boosting investor confidence and affecting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release Q1 2025 financial results on May 13, 2025, after market close, followed by a conference call at 5:00 p.m.
Why It Matters
Lexicon Pharmaceuticals' Q1 2025 financial results release and conference call may influence stock performance, providing insights into company health and future outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LXRX Stock
What is Lexicon Pharmaceuticals, Inc.'s (LXRX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Lexicon Pharmaceuticals, Inc. (LXRX) has a median price target of $1.20. The highest price target is $6.00 and the lowest is $0.70.
Is LXRX stock a good investment in 2025?
According to current analyst ratings, LXRX has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LXRX stock?
Wall Street analysts predict LXRX stock could reach $1.20 in the next 12 months. This represents a 79.1% increase from the current price of $0.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexicon Pharmaceuticals, Inc.'s business model?
The company utilizes advanced gene knockout technology to discover and develop therapies for various medical conditions, focusing on areas with unmet medical needs. Lexicon Pharmaceuticals generates revenue through the successful development and commercialization of its innovative pharmaceutical products, often collaborating with other organizations to advance its clinical programs.
What is the highest forecasted price for LXRX Lexicon Pharmaceuticals, Inc.?
The highest price target for LXRX is $6.00 from Yasmeen Rahimi at Piper Sandler, which represents a 795.5% increase from the current price of $0.67.
What is the lowest forecasted price for LXRX Lexicon Pharmaceuticals, Inc.?
The lowest price target for LXRX is $0.70 from at , which represents a 4.5% increase from the current price of $0.67.
What is the overall LXRX consensus from analysts for Lexicon Pharmaceuticals, Inc.?
The overall analyst consensus for LXRX is bullish. Out of 10 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $1.20.
How accurate are LXRX stock price projections?
Stock price projections, including those for Lexicon Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 2:45 AM UTC